The Role of ASIC1a in Inflammatory Immune Diseases: A Potential Therapeutic Target

Yinghong Wang; Xiaojie Hu; Yancai Sun; Yan Huang

doi:10.3389/fphar.2022.942209

Frontiers in Pharmacology (Jul 2022)

The Role of ASIC1a in Inflammatory Immune Diseases: A Potential Therapeutic Target

Yinghong Wang,
Xiaojie Hu,
Yancai Sun,
Yan Huang

Affiliations

Yinghong Wang: Department of Pharmacy, Anhui Provincial Cancer Hospital, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China
Xiaojie Hu: Anhui Provincial Laboratory of Inflammatory and Immunity Disease, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei, China
Yancai Sun: Department of Pharmacy, Anhui Provincial Cancer Hospital, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China
Yan Huang: Anhui Provincial Laboratory of Inflammatory and Immunity Disease, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei, China

DOI: https://doi.org/10.3389/fphar.2022.942209
Journal volume & issue: Vol. 13

Abstract

Read online

It is acknowledged that chronic inflammation is associated with a rise in extracellular proton concentrations. The acid-sensing ion channel 1a (ASIC1a) belongs to the extracellular H+-activated cation channel family. Recently, many studies have been conducted on ASIC1a and inflammatory immune diseases. Here, in this review, we will focus on the role of ASIC1a in several inflammatory immune diseases so as to provide new perspectives for clinical treatment.

Published in Frontiers in Pharmacology

ISSN: 1663-9812 (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Therapeutics. Pharmacology
Website: http://journal.frontiersin.org/journals/pharmacology

About the journal

Abstract

Keywords